Chang Wei Qing Decoction enhances the anti-tumor effect of PD-1 inhibitor therapy by regulating the immune microenvironment and gut microbiota in colorectal cancer.
10.1016/S1875-5364(23)60451-0
- Author:
Ting WANG
1
,
2
;
Linguangjin WU
1
,
3
;
Shuyun WANG
1
,
3
;
Xiaolan SHI
4
;
Hui LIU
5
;
Wanli DENG
6
Author Information
1. Department of Oncology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China
2. Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. Electronic address: wangting9485@163.com.
3. Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
4. Department of Oncology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China. Electronic address: lan701206@163.com.
5. Department of Oncology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China. Electronic address: liuhui79@shutcm.edu.cn.
6. Department of Oncology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China. Electronic address: dengwanli2631@shutcm.edu.cn.
- Publication Type:Journal Article
- Keywords:
CD8(+) T cells;
Chang Wei Qing;
Gut microbiota;
PD-1 inhibitor therapy;
Tumor immune microenvironment
- MeSH:
Animals;
Mice;
Immune Checkpoint Inhibitors/therapeutic use*;
Gastrointestinal Microbiome;
CD8-Positive T-Lymphocytes;
B7-H1 Antigen;
RNA, Ribosomal, 16S;
Colorectal Neoplasms/metabolism*;
Colonic Neoplasms;
Tumor Microenvironment
- From:
Chinese Journal of Natural Medicines (English Ed.)
2023;21(5):333-345
- CountryChina
- Language:English
-
Abstract:
The anti-tumor effect of anti-PD-1 antibody has long been shown to be strongly related to the tumor immune microenvironment (TIME). This study aimed to mechanistically assess whether Chang Wei Qing (CWQ) Decoction can enhance the anti-tumor effect of PD-1 inhibitor therapy. PD-1 inhibitor therapy showed the significant anti-tumor effect in patients with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC), rather than those with mismatch repair-proficient/microsatellite stable (pMMR/MSS) CRC. Hence, immunofluorescence double-label staining was utilized to explore the difference in the TIME between dMMR/MSI-H and pMMR/MSS CRC patients. Flow cytometry was used to analyze T-lymphocytes in tumors from mice. Western blot was used to measure the expression of PD-L1 protein in mouse tumors. The intestinal mucosal barrier of mice was evaluated by hematoxylin-eosin staining and immunohistochemistry. 16S rRNA-gene sequencing was used to examine the structure of the gut microbiota in mice. Subsequently, Spearmanapos;s correlation analysis was used to analyze the relationship between the gut microbiota and tumor-infiltrating T-lymphocytes. The results showed that dMMR/MSI-H CRC patients had more CD8+T cells and higher expression of PD-1 and PD-L1 proteins. In vivo, CWQ enhanced the anti-tumor effect of anti-PD-1 antibody and increased the infiltration of CD8+ and PD-1+CD8+ T cells in tumors. Additionally, the combination of CWQ with anti-PD-1 antibody resulted in lower inflammation in the intestinal mucosa than that induced by anti-PD-1 antibody alone. CWQ and anti-PD-1 antibody co-treatment upregulated PD-L1 protein and reduced the abundance of Bacteroides in the gut microbiota but increased the abundance of Akkermansia,Firmicutes, andActinobacteria. Additionally, the proportion of infiltrated CD8+PD-1+, CD8+, and CD3+ T cells were found to be positively correlated with the abundance of Akkermansia. Accordingly, CWQ may modulate the TIME by modifying the gut microbiota and consequently enhance the anti-tumor effect of PD-1 inhibitor therapy.
